Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-04-23
- Target Recruit Count
- 315
- Registration Number
- NCT06192160
- Locations
- 🇧🇼
12701, Gaborone CRS, Gaborone, Botswana
🇧🇷12201, Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Brazil
🇧🇷12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio De Janeiro, Brazil
Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection
- Conditions
- Prosthetic-joint InfectionInfection; Knee, JointInfection Hip
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 316
- Registration Number
- NCT06172010
- Locations
- 🇳🇱
Alrijne Ziekenhuis, Leiderdorp, Netherlands
🇳🇱Amsterdam UMC, Amsterdam, Netherlands
🇳🇱Martini ziekenhuis, Groningen, Netherlands
A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets
- Conditions
- Advanced Malignant Neoplasm
- Interventions
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06165822
- Locations
- 🇨🇳
The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT06162169
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University College, London
- Target Recruit Count
- 2500
- Registration Number
- NCT06114628
- Locations
- 🇿🇦
TASK Eden, George, South Africa
🇹🇿NIMR Mbeya, Mbeya, Tanzania
🇿🇦TASK Brooklyn, Cape Town, South Africa
A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Methotrexate in Elderly Subjects
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06108453
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
Drug-Drug Interaction (DDI) Study for TPN171H
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Vigonvita Life Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT06090123
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT06089733
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT06064539
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
Pragmatic Optimized Rifampicin Trial
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 164
- Registration Number
- NCT06057519
- Locations
- 🇳🇱
Radboud University Medical Centre, Nijmegen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.